Interviews
News Flash
JnJ registers 6.6% growth in Q3, 2005
19 Oct '05
3 min read
Multi-national company Johnson & Johnson (JnJ) announced sales for the third quarter of $12.3 billion, an increase of 6.6 percent over the prior year. The increase represented operational growth of 5.8 percent and a favorable currency impact of .8 percent.
Domestic sales were up 2.6 percent, while international sales increased 12.2 percent, reflecting operational growth of 10.3 percent and a positive currency impact of 1.9 percent.
Net earnings and diluted earnings per share for the third quarter were $2.6 billion and $.87, increases of 12.1 percent and 11.5 percent, respectively, as compared to the same period in 2004. Prior-year third quarter net earnings included after-tax in-process research and development charges of $12 million associated with the acquisition of Scott Lab, Inc.
William C. Weldon, Chairman and Chief Executive Officer stated that their broadly based approach to businesses in support of human health care continues to serve us well. The strong performance of their worldwide Medical Devices and Diagnostics and Consumer segments resulted in solid growth for Johnson & Johnson despite the competitive challenges that their Pharmaceutical business has experienced.
Worldwide Medical Devices and Diagnostics sales of $4.6 billion for the third quarter represented an increase over the prior year of 14.3 percent with operational growth of 13.7 percent and a positive impact from currency of .6 percent. Domestic sales increased 14.1 percent, while international sales increased 14.5 percent (13.3 percent from operations and 1.2 percent from currency).
Domestic sales were up 2.6 percent, while international sales increased 12.2 percent, reflecting operational growth of 10.3 percent and a positive currency impact of 1.9 percent.
Net earnings and diluted earnings per share for the third quarter were $2.6 billion and $.87, increases of 12.1 percent and 11.5 percent, respectively, as compared to the same period in 2004. Prior-year third quarter net earnings included after-tax in-process research and development charges of $12 million associated with the acquisition of Scott Lab, Inc.
William C. Weldon, Chairman and Chief Executive Officer stated that their broadly based approach to businesses in support of human health care continues to serve us well. The strong performance of their worldwide Medical Devices and Diagnostics and Consumer segments resulted in solid growth for Johnson & Johnson despite the competitive challenges that their Pharmaceutical business has experienced.
Worldwide Medical Devices and Diagnostics sales of $4.6 billion for the third quarter represented an increase over the prior year of 14.3 percent with operational growth of 13.7 percent and a positive impact from currency of .6 percent. Domestic sales increased 14.1 percent, while international sales increased 14.5 percent (13.3 percent from operations and 1.2 percent from currency).
Popular News
Leave your Comments
Esteemed Clients
-Ltd..jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Thermore (Far East) Ltd.")
.jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Telangana State Industrial Infrastructure Corporation Limited (TSllC Ltd)")
.jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Taiwan Textile Federation (TTF)")
